Oman Pharmaceuticals and Healthcare Industry Update Quarter 1 2012

  • November 2013
  • -
  • Business Monitor International
  • -
  • 102 pages

BMI View: While Oman is viewed favourably in terms of operating risks, constraints on medicine pricing and the small population will continue to drag down its rewards score. Nevertheless, oil revenues should continue to underpin government’s efforts to provide modern healthcare, while the demand for latest treatments will continue to strengthen on the back of the populations’ preference for branded drugs.

Headline Expenditure Projections
- Pharmaceuticals: OMR117mn (US Dollar 303mn) in 2010 to OMR125mn (US Dollar 326mn) in 2011; +7.7% in both local currency and US dollar terms. Projection slightly down from Q411, with 2010 values revised downwards due to new trade data.
- Healthcare: OMR605mn (US Dollar 1.57bn) in 2010 to OMR663mn (US Dollar 1.72bn) in 2011; +9.6% in both local currency and US dollar terms. Projection unchanged from Q411, although 2010 value revised upwards due to new macroeconomic data.
- Medical devices: OMR33mn (US Dollar 86mn) in 2010 to OMR38mn (US Dollar 98mn) in 2011; +13.1% in both local currency and US dollar terms. Projection revised upwards significantly from Q411 due to macroeconomic factors, although 2010 values revised downwards due to new trade data.
Business Environment Rating: Oman’s composite score improved by 4.1% quarter-to-quarter (q-oq) and now stands at 50.2 out of the maximum 100 points. This has resulted in the country rising by one place to ninth in the Q112 Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for Middle East and Africa (MEA). Oman is one of the smallest regional industries, which drags down its rewards score, but has relatively low operating risks in regional terms.

Key Trends & Developments
- As part of their commitment to tackling cancer, and coinciding with the World’s Breast Cancer awareness month, the Ministry of Justice inaugurated a walkathon in Oman. The October 2011 event was themed ‘Say You Care, Be Aware’, in order to promote self-examination and early breast cancer diagnosis. Around the same time, the National Association for Cancer Awareness (NACA) installed Mobile Mammography Units (MMUs) at various locations in the interior regions of Oman, reported Oman Daily Observer, citing the association. The moves are also expected to increase awareness about breast cancer as well as other forms of the disease.
- In October 2011, the authorities were reported to be in the process of implementing several government-funded projects in the country, as add-ons to the Five-Year Development Plan 2011- 2015. The projects, which include the construction of a referral hospital, will specifically target less developed areas of the sultanate.
- Oman's Ministry of Health (MoH) aims to promote e-health services by linking identity cards (IDs) with hospital registration and treatment, reported Muscat Daily in September 2011. According to the country manager of Muscat Private Hospital, Michael Sheldon, e-health services enable doctors to identify the main cause of a disease by referring to the medical history of individual patients.
- India is shortly expected to conclude free trade agreement (FTA) talks with all the member states of the Gulf Cooperation Council (GCC). These talks began officially in 2006, following the 2004 signing of the Framework Agreement on Economic Cooperation, which paved the way for the current negotiations. The FTA should help Indian drugmakers to take a greater industry share of the regional generic drug sector, primarily at the expense of Middle Eastern drugmakers.
BMI Economic View: As a result of increased income from oil exports, we expect Oman's finances to remain in good shape this year. Heightened revenues have been offset to some extent by a concurrent rise in public spending, but we nevertheless expect the budget to register a surplus of 4.7% of Gross Domestic Product in 2011, up from a deficit of 0.3% in 2010. Looking forward, we expect moderating energy prices and further spending increases to restrict the budget surplus to 1.0% of Gross Domestic Product in 2012, which may also constrain the government’s healthcare spending.
BMI Political View: Public protests in Oman have continued despite a series of government reforms aimed at creating more employment opportunities and ceding powers to the parliament. While we believe tensions may persist, we expect the current government to survive the unrest without having to make significant political concessions. The government has been extremely proactive in addressing one of the main demands of protestors – increased employment opportunities, which will also improve the prospects for non-prescription drug spending as well as for the wider healthcare services use.

Table Of Contents

Executive Summary. 5
Industry SWOT Analysis .. 7
Oman Pharmaceuticals And Healthcare Industry Environment and Risk Analysis .. 7
Oman Political Environment and Risk Analysis . 8
Oman Economic Environment and Risk Analysis . 8
Oman Business Environment SWOT .. 9
Pharmaceutical Business Environment Ratings. 10
Data : Middle East And Africa (MEA) - Regional Pharmaceutical Business Environment Ratings, Q112 11
Rewards .. 12
Risks.. 13
Oman - Industry Summary.. 15
Regulatory Regime 16
Recent Regulatory Developments 17
Intellectual Property Regime 18
Data : Current IP Laws In Oman .. 18
Pricing and Reimbursement.. 19
Regional Harmonisation. 20
Free Trade Agreements 22

Industry Developments .. 24
Epidemiology 24
Data : Oman Mortality Indicators, 2006 24
Communicable Diseases . 25
Non-Communicable Diseases .. 26
Recent Public Health Developments . 27
Healthcare Segment .. 28
Data : Number Of Health Centres In Oman, By Region . 28
Data : Healthcare Reform Targets. 29
Data : Number And Type Of Health Institutions In Oman . 30
Private Healthcare Segment .. 31
Healthcare Insurance 33
Telemedicine. 33
Medical Tourism. 34
International Healthcare Collaboration . 35
Research and Biotechnology. 36
Clinical Trials.. 37
Medical Devices.. 37

Market Projection Scenario .. 39
Overall Industry Projections .. 39
Data : Pharmaceutical Sales, Historical Data and Projection, from 2007 to 2016 40
Healthcare Industry Projection . 41
Data : Healthcare, Historical Data and Projection, from 2007 to 2016 . 42
Key Growth Factors - Macroeconomic .. 43
Data : Oman - Economic Activity.. 46
Prescription Drug Industry Projection .. 47
Data : Pharmaceutical Prescription Drug Sales, Historical Data and Projection, from 2007 to 2016 48
Patented Drug Industry Projection . 49
Data : Pharmaceutical Patented Drug Sales, Historical Data and Projection, from 2007 to 2016 50
Generic Drug Industry Projection 51
Data : Pharmaceutical Generic Drug Sales, Historical Data and Projection, from 2007 to 2016 . 52
OTC Medicine Industry Projection . 53
Data : Pharmaceutical OTC Medicine Sales, Historical Data and Projection, from 2007 to 2016 54
Medical Device Industry Projection 55
Data : Medical Device Sales, Historical Data and Projection, from 2007 to 2016 56
Pharmaceutical Trade Projection .. 57
Data : Pharmaceutical Trade, Historical Data and Projection, from 2007 to 2016 .. 59
Other Healthcare Data Projections .. 60
Key Risk to BMI’s Projections . 61

Competition Overview . 62
Pharmaceutical Segment . 62
Data : Registered Pharmaceutical Firms And Products.. 62
Domestic Market .. 62
Foreign Market . 64
Pharmaceutical Distribution. 64
Company Monitor .. 65
Indigenous Manufacturers 65
Zynova/Oman Pharmaceutical Products Firms (OPPC). 65
National Pharmaceutical Market (NPI). 68
Multinationals. 70
Novartis .. 70
GlaxoSmithKline. 72
Sanofi-Aventis.. 73
Johnson and Johnson 74
Country Snapshot: Oman Demographic Data .. 75

Section I : Population 75
Data : Demographic Indicators, 2005-2030. 75
Data : Rural/Urban Breakdown, 2005-2030. 76

Section II : Education and Healthcare 76
Data : Education, from 2002 to 2005 76
Data : Vital Statistics, 2005-2030.. 76

Section III : Labour Industry and Spending Power.. 77
Data : Employment Indicators, 1999-2004 77
Data : Consumer Expenditure, from 2000 to 2012 (US$) .. 77
Glossary .. 78
BMI Methodology 80
How We Generate Our Pharmaceutical Market Projections . 80
Pharmaceuticals Business Environment Ratings 81
Risk/Reward Ratings Methodology 81
Ratings Overview 81
Data : Pharmaceutical Business Environment Indicators.. 82
Weighting 83
Data : Weighting Of Components .. 83

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...

Detailed I/E report of Carbendazim export analysis

Detailed I/E report of Carbendazim export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Carbendazim export analysis will help clients indentify export situation of technical and formulations with exclusive research methods, to offer not only the target products' export volume, price, time, ...

Global Pediatric Drugs and Vaccines Market

Global Pediatric Drugs and Vaccines Market

  • $ 4 950
  • Industry report
  • September 2014
  • by Global Industry Analysts

This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective ...

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.